Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treosulfan oral versus intravenous in recurrent ovarian cancer
DRKS00003943Phase 3Completed
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Dec 2012
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of treosulfan in ovarian cancer (2 arms), sponsored by Universitätsklinikum Freiburg. Started Dec 2012; status: completed.
02
Drugs
treosulfan
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on DRKS00003943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00003943.